Interim analysis findings showed the perioperative treatment group demonstrated a statistically significant improvement in event-free survival compared with adjuvant radiotherapy, with or without ...

Participants (median age, 58.5 years) received intravenous pembrolizumab (200 mg) every 21 days for up to 2 years or until disease progression, with a maximum of 35 cycles. Tumour assessments ...

Thirty-seven patients received four doses of bevacizumab and pembrolizumab every 3 weeks followed by up to 2 years of pembrolizumab. The brain metastasis response rate (primary end point) was 54.1% ...

Five PD-L1 Antibodies Tested: Only MHC-II correlated with response to pembrolizumab, whereas none of the five PD-L1 measurements reached statistical significance. Improved Patient Outcomes ...

The clinical efficacy of enfortumab vedotin plus pembrolizumab in real-world patients is compatible with that of the phase 3 EV-302 clinical trial. Treatment with enfortumab vedotin plus ...